{
  "@context": "https://schema.org",
  "@type": "Dataset",
  "name": "SemaglutideGLPOne.com Methodology — Six-Pillar v3.0 Transparency Rubric",
  "description": "Editorial scoring methodology for ranking U.S. compounded semaglutide telehealth providers.",
  "url": "https://semaglutideglpone.com/data/methodology.json",
  "datePublished": "2026-05-22",
  "version": "3.0",
  "scale_total_points": 100,
  "passing_threshold_per_pillar": 0.70,
  "pillars": [
    {
      "id": 1,
      "name": "Clinical protocol & physician of record",
      "max_points": 20,
      "criteria": [
        "Named medical director with publicly verifiable state licensure",
        "Individualized prescribing (no standing-order model)",
        "Documented contraindication screening",
        "Side-effect management protocol",
        "Telehealth practice meets state-specific requirements"
      ]
    },
    {
      "id": 2,
      "name": "Pharmacy traceability & CoA",
      "max_points": 20,
      "criteria": [
        "Named 503A or 503B pharmacy partners",
        "USP <71> sterility documentation",
        "USP <85> endotoxin documentation",
        "HPLC potency Certificate of Analysis available",
        "API source verified as semaglutide base (not salt forms)"
      ]
    },
    {
      "id": 3,
      "name": "Real-world cohort outcomes & adverse event disclosure",
      "max_points": 20,
      "criteria": [
        "Published cohort outcomes at 12, 26, and 52 weeks",
        "Adverse-event disclosure with rates",
        "Discontinuation rates published",
        "No misleading claims about FDA approval or efficacy"
      ]
    },
    {
      "id": 4,
      "name": "All-inclusive flat pricing",
      "max_points": 15,
      "criteria": [
        "Same price across 0.25 → 2.4 mg titration",
        "No dose-based upcharges",
        "No surprise fees (lab, visit, shipping)",
        "Refund/cancellation policy public"
      ]
    },
    {
      "id": 5,
      "name": "Lab integration & longitudinal follow-up",
      "max_points": 15,
      "criteria": [
        "Quest or Labcorp integration",
        "Baseline panel before Rx (CBC, CMP, lipids, HbA1c, TSH, beta-hCG)",
        "Check-ins at 4, 12, 26, and 52 weeks",
        "Labs covered in program cost"
      ]
    },
    {
      "id": 6,
      "name": "Regulatory clarity (base vs salt)",
      "max_points": 10,
      "criteria": [
        "API form disclosed in writing (semaglutide base required)",
        "Compliance with April 14, 2026 FDA action",
        "No use of semaglutide sodium or acetate (salt forms)",
        "LegitScript certification (preferred)"
      ]
    }
  ]
}